These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 30844110)

  • 1. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
    Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR
    Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.
    Lin K; Cheng J; Yang T; Li Y; Zhu B
    Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):95-101. PubMed ID: 25998384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
    Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
    J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
    Azuma K; Ota K; Kawahara A; Hattori S; Iwama E; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Ann Oncol; 2014 Oct; 25(10):1935-1940. PubMed ID: 25009014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
    J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].
    Shi Y; Lv W; Wang L; Hu J
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):781-786. PubMed ID: 29167009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.
    Grant CE; Flis AL; Toulabi L; Zingone A; Rossi E; Aploks K; Sheppard H; Ryan BM
    Mol Oncol; 2024 Jun; 18(6):1631-1648. PubMed ID: 38572507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.